Neuroprotective Effects of Risperdal on Brain and Cognition in 22q11 Deletion Syndrome

Key facts

Sponsor

University of Geneva, Switzerland

Principal Investigator

Stephan Eliez, Professor

University of Geneva, faculty of medicine

Intervention

Risperdal(drug)

Enrollment

16 enrolled

Eligibility

11-25 years · All sexes

Timeline

2017 – 2021

Study locations (1)

• Developmental imaging and psychopathology lab, Geneva, Switzerland

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for 22q11.2 deletion syndrome

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT05664412
  Using Transcranial Alternating Current Stimulation to Improve Executive Function in 22q11.2 Deletion Syndrome
  Stephan Eliez
• RECRUITINGNCT05924347
  Early Scoliotic Changes in Children at Increased Risk for Scoliosis Development
  UMC Utrecht
• RECRUITINGNCT05329935
  Congenital Athymia Patient Registry
  Sumitomo Pharma Switzerland GmbH
• RECRUITINGNANCT04639388
  Understanding of Psychotic Disorders in Children With 22q11.2DS
  Hôpital le Vinatier
• RECRUITINGNCT00556530
  Examining Genetic Factors That Affect the Severity of 22q11.2 Deletion Syndrome
  Albert Einstein College of Medicine

See all trials for 22q11.2 deletion syndrome →